Amera Morad Foad, Alshimaa Hafez, Wael Youssef, Ahmed Elsharawy Ahmed, Ali Mohamad Altaher
{"title":"Irisin expression and <i>FNDC5</i> (rs3480) gene polymorphism in type 2 diabetic patients with and without CAD.","authors":"Amera Morad Foad, Alshimaa Hafez, Wael Youssef, Ahmed Elsharawy Ahmed, Ali Mohamad Altaher","doi":"10.1080/13813455.2023.2173785","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Irisin was found to correlate with coronary artery disease (CAD) in diabetic patients. This study investigated the association of irisin and <i>FNDC5</i> (SNP rs3480) with the presence and severity of CAD in T2DM.</p><p><strong>Methods: </strong>This cross-sectional study included 100 patients with T2DM divided into two groups, DM group (<i>n</i> = 50), including patients without CAD and CAD group (<i>n</i> = 50), including those confirmed to have CAD by coronary angiography. Irisin was measured. SNP rs3480 genotyping of <i>FNDC5</i> was done.</p><p><strong>Results: </strong>Irisin levels were significantly lower in the CAD group (<i>p</i> < 0.001). The CAD group had significantly higher HbA1c and lower HDL (<i>p</i> < 0.001). Patients with controlled DM had significantly higher irisin levels (<i>p</i> < 0.001). single nucleotide polymorphism (SNP) rs3480 was not associated with irisin levels, and the <i>FNDC5</i> rs3480 AA reference allele was significantly associated with significant CAD.</p><p><strong>Conclusion: </strong>Irisin appears to be protective against developing CAD in diabetic patients. Irisin level was an independent predictor of significant CAD in diabetic patients combined with the <i>FNDC5</i> rs3480 genotype.</p><p><strong>Clinical trial registration number: </strong>NCT04957823.</p>","PeriodicalId":8331,"journal":{"name":"Archives of Physiology and Biochemistry","volume":" ","pages":"523-528"},"PeriodicalIF":2.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Physiology and Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13813455.2023.2173785","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/2/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Irisin was found to correlate with coronary artery disease (CAD) in diabetic patients. This study investigated the association of irisin and FNDC5 (SNP rs3480) with the presence and severity of CAD in T2DM.
Methods: This cross-sectional study included 100 patients with T2DM divided into two groups, DM group (n = 50), including patients without CAD and CAD group (n = 50), including those confirmed to have CAD by coronary angiography. Irisin was measured. SNP rs3480 genotyping of FNDC5 was done.
Results: Irisin levels were significantly lower in the CAD group (p < 0.001). The CAD group had significantly higher HbA1c and lower HDL (p < 0.001). Patients with controlled DM had significantly higher irisin levels (p < 0.001). single nucleotide polymorphism (SNP) rs3480 was not associated with irisin levels, and the FNDC5 rs3480 AA reference allele was significantly associated with significant CAD.
Conclusion: Irisin appears to be protective against developing CAD in diabetic patients. Irisin level was an independent predictor of significant CAD in diabetic patients combined with the FNDC5 rs3480 genotype.
期刊介绍:
Archives of Physiology and Biochemistry: The Journal of Metabolic Diseases is an international peer-reviewed journal which has been relaunched to meet the increasing demand for integrated publication on molecular, biochemical and cellular aspects of metabolic diseases, as well as clinical and therapeutic strategies for their treatment. It publishes full-length original articles, rapid papers, reviews and mini-reviews on selected topics. It is the overall goal of the journal to disseminate novel approaches to an improved understanding of major metabolic disorders.
The scope encompasses all topics related to the molecular and cellular pathophysiology of metabolic diseases like obesity, type 2 diabetes and the metabolic syndrome, and their associated complications.
Clinical studies are considered as an integral part of the Journal and should be related to one of the following topics:
-Dysregulation of hormone receptors and signal transduction
-Contribution of gene variants and gene regulatory processes
-Impairment of intermediary metabolism at the cellular level
-Secretion and metabolism of peptides and other factors that mediate cellular crosstalk
-Therapeutic strategies for managing metabolic diseases
Special issues dedicated to topics in the field will be published regularly.